Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Sells $3,895,000.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CFO Robert Thomas Freeman sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $15.58, for a total transaction of $3,895,000.00. Following the transaction, the chief financial officer now directly owns 1,635,849 shares of the company’s stock, valued at $25,486,527.42. This represents a 13.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Robert Thomas Freeman also recently made the following trade(s):

• On Thursday, March 6th, Robert Thomas Freeman sold 218,295 shares of Alignment Healthcare stock. The stock was sold at an average price of $15.53, for a total transaction of $3,390,121.35.

Alignment Healthcare Trading Down 3.5 %

NASDAQ ALHC opened at $15.25 on Friday. The firm’s 50-day moving average is $13.89 and its two-hundred day moving average is $12.14. Alignment Healthcare, Inc. has a 12 month low of $4.46 and a 12 month high of $16.25. The company has a debt-to-equity ratio of 1.82, a current ratio of 1.60 and a quick ratio of 1.60. The stock has a market capitalization of $2.93 billion, a P/E ratio of -19.81 and a beta of 1.49.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. lifted their target price on shares of Alignment Healthcare from $14.00 to $17.00 and gave the company a “neutral” rating in a report on Thursday. Stephens reaffirmed an “overweight” rating and set a $17.00 target price on shares of Alignment Healthcare in a report on Monday, February 24th. Barclays lifted their target price on shares of Alignment Healthcare from $8.00 to $9.00 and gave the stock an “underweight” rating in a research note on Friday, February 28th. Bank of America lifted their target price on shares of Alignment Healthcare from $15.50 to $18.50 and gave the stock a “buy” rating in a research note on Tuesday. Finally, William Blair reaffirmed an “outperform” rating on shares of Alignment Healthcare in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Alignment Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.83.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ALHC. R Squared Ltd acquired a new position in Alignment Healthcare in the fourth quarter valued at about $55,000. RiverPark Advisors LLC purchased a new stake in Alignment Healthcare during the fourth quarter worth about $106,000. Tower Research Capital LLC TRC increased its stake in Alignment Healthcare by 146.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,571 shares of the company’s stock worth $119,000 after purchasing an additional 6,286 shares during the period. Ballentine Partners LLC purchased a new stake in Alignment Healthcare during the fourth quarter worth about $121,000. Finally, Aigen Investment Management LP purchased a new stake in Alignment Healthcare during the fourth quarter worth about $129,000. Institutional investors and hedge funds own 86.19% of the company’s stock.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.